Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q2 2018 call → NOWe need to determine if management conveys that successive engagements of the same kind are coming in at progressively larger size. The question asks: does management describe that the company's deals, orders, contracts, projects, customers, sites, or programs are individually bigger, broader, or longer than before for the same offering? We need to look for evidence in the transcript. Let's scan the transcript for any statements about increasing size of deals, contracts, or projects. The discussion covers revenue growth, volume growth, pricing, labor, crude by rail, potash, etc. But we need specifically about the unit size of repeatable business escalating. Key points: John Brooks talks about pricing, renewals, same-store price. He mentions "renewal pricing was strong" and "same-store price came in at the high end of our 3% to 4% targeted range." That's about price, not size of deals. Keith Creel talks about growth, capacity, and being disciplined. He mentions "capacity is currency" and picking partners. But no mention of deals being larger. There is discussion about crude by rail: "we did 20,000 carloads in Q2" and potential to double run rate by end of 2018. That's about volume, not necessarily size of individual contracts. They talk about "opportunity to expand" but not about individual contracts being larger. Potash: "record amount of potash in Q2" and "strong potash demand will continue." Again volume. No mention of average order size, contract value, or scope expansion per customer. The question specifically asks about "successive engagements of the same kind" coming in at "progressively larger size." There is no such statement. Management talks about growth in volumes, revenue, and pricing, but not about individual deals being bigger. Thus, answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.